Marksans Pharma Ltd

Net profit of Marksans Pharma rose 8.26% to Rs 113.20 crore in the quarter ended December 2025 as against Rs 104.56 crore during the previous quarter ended December 2024. Sales rose 10.64% to Rs 754.43 crore in the quarter ended December 2025 as against Rs 681.85 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales754.43681.85 11 OPM %21.3120.35 - PBDT174.95163.95 7 PBT150.62143.26 5 NP113.20104.56 8 Powered by Capital Market - Live

Profit before tax (PBT) declined 5.13% YoY to Rs 150.62 crore during the quarter. EBITDA increased 23.2% YoY to Rs 160.7 crore in Q3 FY26, compared with Rs 130.5 crore posted in Q3 FY25. EBITDA margin improved to 21.3% in Q3 FY26 from 19.1% in Q3 FY25. During the quarter, revenue from the US and North America stood at Rs 412.4 crore (up 16.9% YoY), while revenue from the UK and Europe stood at Rs 258.2 crore (up 0.2% YoY). Revenue from Australia and New Zealand stood at Rs 61.4 crore (up 30.1% YoY) in Q3 FY26. Revenue from the Rest of the World (RoW) declined 7.2% YoY to Rs 22.4 crore during the period under review. As of 31 December 2025, the company's cash balance stood at Rs 824.2 crore. Research and development (R&D) expenditure for 9MFY26 was Rs 62 crore, accounting for 3% of consolidated revenue. Mark Saldanha, managing director of the company, said, 'We delivered a stable and resilient performance in Q3 FY26, with operating revenue growing 10.6% YoY, supported by steady execution across key markets and improved seasonal demand. Margins expanded sequentially, driven by soft raw material costs, favorable currency movements, and an improving product mix, while EBITDA growth reflected operating leverage. During the quarter, we took measured steps to strengthen our global footprint through new subsidiaries in Europe and Canada, positioning the company for long-term growth in regulated markets. We remain disciplined, execution-focused, and committed to delivering sustainable growth and long-term shareholder value.' Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. Powered by Capital Market - Live

Marksans Pharma has formed and incorporated the following two new wholly owned subsidiary companies: 1. Marksans Pharma (Europe) in Ireland 2. Marksans (Canada) Inc. in Canada Powered by Capital Market - Live

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution from UK MHRA. Powered by Capital Market - Live

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860). Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharma's portfolio in the US generic pharmaceutical market. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The company's consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25. Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE. Powered by Capital Market - Live

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Marksans Pharma Inc.'s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860.  Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.Powered by Capital Market - Live

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its following products from UK MHRA: 1. Mefenamic Acid 250 mg Film-Coated Tablets 2. Mefenamic Acid 500 mg Film-Coated TabletsPowered by Capital Market - Live

Net profit of Marksans Pharma rose 1.58% to Rs 98.25 crore in the quarter ended September 2025 as against Rs 96.72 crore during the previous quarter ended September 2024. Sales rose 12.23% to Rs 720.41 crore in the quarter ended September 2025 as against Rs 641.92 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales720.41641.92 12 OPM %20.0622.87 - PBDT160.25144.11 11 PBT133.33124.60 7 NP98.2596.72 2 Powered by Capital Market - Live

The key equity indices traded with substantial gains in the mid-afternoon trade. Investors tracked ongoing, corporate earnings, crude oil price and global cues for further direction. The Nifty traded below the 25,600 level. Consumer durables shares advanced after declining in the past two trading sessions. At 14:25 IST, the barometer index, the S&P BSE Sensex advanced 499.45 points or 0.60% to 83,715.73. The Nifty 50 index added 144.80 points or 0.57% to 25,637.10. In the broader market, the S&P BSE Mid-Cap index rose 0.76% and the S&P BSE Small-Cap index shed 0.21%. The market breadth was negative. On the BSE, 2,015 shares rose and 2,249 shares fell. A total of 192 shares were unchanged. Economy: India's foreign exchange reserves fell by $5.6 billion to $689.73 billion in the week ended October 31, 2025, the Reserve Bank of India (RBI) said on Friday. For the week ended October 31, foreign currency assets, a major component of the reserves, decreased by $1.9 billion to $564.59 billion, the RBI data showed. Value of gold reserves declined by $3.8 billion to $101.72 billion during the week, the RBI said. The Special Drawing Rights (SDRs) were down by $19 million to $18.64 billion, the apex bank said. Meanwhile, India's reserve position with the IMF was up by $16.4 million at $4.77 billion in the reporting week, the data showed. Buzzing Index: The Nifty consumer durables index advanced 0.52% to 37,812.40. The index declined 2.68% in the past two consecutive trading sessions. Voltas (up 2%), Crompton Greaves Consumer Electricals (up 1.62%), PG Electroplast (up 1.32%), Blue Star (up 1.24%), Titan Company (up 0.82%), Dixon Technologies (India) (up 0.63%), Havells India (up 0.56%) advanced. Numbers to Track: The yield on India's 10-year benchmark federal paper was down 0.28% to 6.503 as compared with previous close 6.521. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 88.6975 compared with its close of 88.6500 during the previous trading session. MCX Gold futures for 5 December 2025 settlement rose 1.79% to Rs 123,240. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.09% to 99.51. The United States 10-year bond yield rose 1.12% to 4.139. In the commodities market, Brent crude for December 2025 settlement advanced 32 cents or 0.50% to $63.95 a barrel. Stocks in Spotlight: Marksans Pharma rose 1.86% after the company announced that it has received zero observations in a current Good Manufacturing Practice (cGMP) inspection conducted by the US Food and Drug Administration (USFDA) at its Goa facility. SMS Pharmaceuticals rallied 3.24% after the company's consolidated net profit jumped 79.5% to Rs 25.31 crore on 23.2% increase in revenue from operations to Rs 242.43 crore in Q2 FY26 over Q2 FY25.Powered by Capital Market - Live